
Consider the four “P’s” of generic drugs that support the case for wider adoption of generics in the health system and beyond.
340B experts share how to ensure your program is delivering the best to patients and providers.
Date
September 01, 2021
By McKesson Health Systems Editorial Team
Read time: 6 minutes
A Q&A with three 340B experts reveals where to start with ensuring your hospital or health system has a strong 340B program.
From building the foundation to choosing the right platforms, download this white paper to find out the keys to building and maintaining a successful program that delivers.
Consider the four “P’s” of generic drugs that support the case for wider adoption of generics in the health system and beyond.
One of our McKesson experts discusses the importance of staying informed as 340B changes continue to unfold.
The most downloaded content by health system pharmacy leaders in August 2025.
With available labor resources dwindling and a shrinking pipeline, health systems must find creative solutions for better using the personnel and partnerships they have.
Expert insights into prioritizing 340B as a system-wide program in your health system.
The most downloaded content by health system pharmacy leaders in July 2025.
McKesson’s Head of Cell, Gene, and Advanced Therapies discusses opportunities and challenges with CGT in the health system.
This interactive experience highlights key aspects of our SPE solutions, designed to help your health system achieve more.
The first in a series of interviews with our Specialty Pharmacy Enablement expert, Ginger Thorpe, covering important questions health systems should be asking.
The top three Prescribed Perspectives articles downloaded by health systems in June.